Latest News

Committed to the health of your projects during COVID-19

I would like to take a moment and share our commitment to the highest levels of health and improving lives worldwide, amidst the outbreak of COVID-19.

The health of our staff and yours around the globe is of the utmost importance to us. We also understand that the well-being, strengths and skills of MMS colleagues in the United States, Europe, India, and South Africa are essential to the on-time delivery of every project.  We are taking the necessary precautions to ensure that every colleague remains healthy, productive, and committed to supporting your efforts.

Global leaders and human resource professionals at MMS have responded swiftly to ensure that best practices in addressing concerns specific to the COVID-19 threat are in place, communicated, and practiced.  This includes a robust Business Continuity and Disaster Recovery (BCDR) plan, inclusive of remote work accommodations, to maintain the support you have come to expect from MMS for your projects.

In light of similar industry policies, we are limiting all non-essential travel to ensure the safety of your teams and ours. If you have any questions related to this, please reach out to your assigned project manager for an immediate response.

Since MMS first opened its doors in 2006, we have been committed to providing a safe workplace for our staff and operating with a Sense Of Urgency and Leadership. It’s the SOUL of MMS. Our mission to improve lives worldwide has never been truer than it is today. We are committed and remain on course, focused on supporting our staff and your projects to the best of our abilities.

On behalf of the entire executive leadership team, thank you for your continued trust in MMS.

Sincerely,

Prasad M. Koppolu

Chief Operating Officer, MMS

PLEASE READ: Six Changes that Pharmaceutical Companies Should Consider in Response to COVID-19

Suggested For You

news

February 12th, 2025

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

news

December 13th, 2023

MMS Supported Lykos Therapeutics: NDA Submitted to FDA for First Psychedelic-Assisted Therapy for PTSD

news

February 21st, 2023

MMS Partners with I-ACT to Advance Children’s Clinical Trials

news

June 27th, 2022

Novel PTSD Treatment Advances Toward Regulatory Evaluation with New Collaboration Between MAPS PBC and MMS Holdings

news

June 11th, 2020

Helping to Accelerate the Search for Solutions to the COVID-19 Crisis

news

June 9th, 2020

IGY Life Sciences Partners with MMS Holdings to Develop Novel COVID-19 Antibody Treatment

news

May 5th, 2020

Green Valley Pharmaceutical And MMS Holdings Collaborate to Gain FDA Approval To Begin Clinical Trial For The First Alzheimer's Drug In 17 Years

news

March 20th, 2020

MMS Announces One Million Dollar Award For Pharmaceutical Companies Developing A Vaccine For COVID-19

news

March 14th, 2016

MMS Funds $1 Million Zika Vaccine Development Award

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development

regulatory intelligence

August 9th, 2024

FDA Updates 2024 Language Access Plan

regulatory intelligence

July 8th, 2024

FDA Works to Reduce the Spread of Misinformation